OR WAIT 15 SECS
The company is investing $64.5 million to open new facilities in Germany and Japan to expand its overall capacity.
Minaris Regenerative Medicine, a contract development and manufacturing organization for cell and gene therapies, announced it is investing $64.5 million into the expansion of its facilities in Europe and Asia.
According to a company press release, the European expansion will focus on a new facility in Ottobrunn, Germany, for clinical and commercial manufacturing and development services for cell and gene therapies. Expected to be operational in 2023, the new site will offer additional cleanrooms, quality control laboratories, warehousing, cryo-storage, and office space.
The company is also opening a new facility in Yokohama, Japan to support its expansion in Asia, the press release said. The site will be dedicated to the commercial manufacturing of regenerative medicine and is set to be operational in October 2022.
“We are very pleased to expand our capacity to support the growing demand of clients who continue to care for an increasing number of patients in the future,” said Dusan Kosijer, managing director of Minaris Regenerative Medicine, in the press release.
Source: Minaris Regenerative Medicine